CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.81B, above the global median of $1.18B
- FinancialsAltman Z-Score 4: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.81BUSDvs all stocks (USD)
Revenue (TTM)
208.78MUSDvs all stocks (USD)
Profit Margin
-37.07%vs Biotechnology peers
Beta
0.6050xvs all stocks
52-Week Change
168.55%vs all stocks
Market Capitalization
2.81BUSDvs all stocks (USD)
Enterprise Value
1.43BUSDvs all stocks (USD)
Forward P/E
-72.31xvs Biotechnology peers
Price to Sales (TTM)
13.48xvs Biotechnology peers
Price to Book (MRQ)
5.53xvs Biotechnology peers
Enterprise to Revenue
6.86xvs Biotechnology peers
Enterprise to EBITDA
-72.49xvs Biotechnology peers
Gross Margin
40.14%vs Biotechnology peers
Profit Margin
-37.07%vs Biotechnology peers
Operating Margin
-29.40%vs Biotechnology peers
Return on Assets (TTM)
-5.71%vs Biotechnology peers
Return on Equity (TTM)
-33.05%vs Biotechnology peers
Revenue (TTM)
208.78MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.43USDUpdated Sep 28, 2026Quarterly Revenue Growth
8.50%vs Biotechnology peers
Gross Profit (TTM)
74.55MUSDvs all stocks (USD)
EBITDA (TTM)
-19.75MUSDvs all stocks (USD)
Net Income (TTM)
-77.39MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.53%vs Biotechnology peers
Operating Cash Flow (TTM)
-25.26MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.62MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
160.33MUSDFY2025 · Dec 31, 2025Revenue
185.74MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
151.75MUSDFY2025 · Dec 31, 2025Gross Profit
33.99MUSDFY2025 · Dec 31, 2025Operating Income
-128.53MUSDvs all stocks (USD)
Pre-tax Income
-234.97MUSDFY2025 · Dec 31, 2025Income Tax Expense
-4.21MUSDFY2025 · Dec 31, 2025Net Income
-230.76MUSDFY2025 · Dec 31, 2025EBIT
-207.98MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-60.77MUSDFY2025 · Dec 31, 2025Research & Development
17.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
145.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.44MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.99MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-230.76MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
99.99MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-139.17MUSDFY2025 · Dec 31, 2025Free Cash Flow
-151.59MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
216.89MUSDFY2025 · Dec 31, 2025Interest Paid
24.98MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-230.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
60.47MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
4.06MUSDFY2025 · Dec 31, 2025Stock-based Compensation
30.17MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.87MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
12.82MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-7.35MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.45MUSDFY2025 · Dec 31, 2025Capital Expenditures
-12.41MUSDFY2025 · Dec 31, 2025Net Acquisitions
-18.99MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-31.41MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-5.44MUSDFY2025 · Dec 31, 2025Other Financing Charges
-11.06MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-16.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
148.89MSharesUpdated Sep 28, 2026Float Shares
114.21MSharesUpdated Sep 28, 2026Shares Short
12.37MSharesUpdated Sep 28, 2026Short Ratio
2.58daysvs all stocks
Short % of Shares Outstanding
9.84%vs all stocks
% Held by Insiders
7.25%vs all stocks
% Held by Institutions
96.79%vs all stocks
Total Cash (MRQ)
70.09MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4700USDUpdated Sep 28, 2026Total Debt (MRQ)
218.10MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6133xvs Biotechnology peers
Current Ratio (MRQ)
4.05xvs Biotechnology peers
Book Value per Share (MRQ)
1.37USDUpdated Sep 28, 2026Total Assets
770.58MUSDvs all stocks (USD)
Total Current Assets
296.25MUSDFY2025 · Dec 31, 2025Total Liabilities
397.87MUSDFY2025 · Dec 31, 2025Total Non-current Assets
474.33MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
352.95MUSDFY2025 · Dec 31, 2025Total Current Liabilities
44.92MUSDFY2025 · Dec 31, 2025Cash
216.89MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
216.89MUSDFY2025 · Dec 31, 2025Accounts Receivable
25.50MUSDFY2025 · Dec 31, 2025Inventory
40.49MUSDFY2025 · Dec 31, 2025Accounts Payable
2.91MUSDFY2025 · Dec 31, 2025Short-term Debt
14.20MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.99MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.89MUSDFY2025 · Dec 31, 2025Long-term Debt
350.51MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
197.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.56MUSDFY2025 · Dec 31, 2025Retained Earnings
10.12MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
372.71MUSDvs all stocks (USD)
52-Week Low
2.54USDUpdated Sep 28, 202652-Week High
9.42USDUpdated Sep 28, 202652-Week Change
168.55%vs all stocks
Beta
0.6050xvs all stocks
50-Day MA
7.02USDUpdated Sep 28, 2026200-Day MA
4.75USDUpdated Sep 28, 2026Avg 10-Day Volume
2.37MSharesUpdated Sep 28, 2026Avg 30-Day Volume
4.06MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.5300USDUpdated Sep 28, 2026Other Income / Expense
-90.89MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.40Profit Margin: -0.37
Financial Health
Altman Z-Score 4: safe zoneNotable
Altman Z-Score: 4.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.81B, above the global median of $1.18BNotable
Market cap (USD): 2,814,718,558Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HLB Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Precigen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rubicon Research Limited
Tier 1ProductionApproval-Gated PipelineRule
Piramal Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curaleaf Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CanSino Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yili Chuanning Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule